These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 973960)

  • 1. The effect of end-stage renal failure and haemodialysis on the elimination kinetics of sotalol.
    Tjandramaga TB; Verbeeck R; Thomas J; Verbesselt R; Verberckmoes R; Schepper PJ
    Br J Clin Pharmacol; 1976 Apr; 3(2):259-65. PubMed ID: 973960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sotalol kinetics in renal insufficiency.
    Blair AD; Burgess ED; Maxwell BM; Cutler RE
    Clin Pharmacol Ther; 1981 Apr; 29(4):457-63. PubMed ID: 7471612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biotransformation and excretion of lorazepam in patients with chronic renal failure.
    Verbeeck R; Tjandramaga TB; Verberckmoes R; De Schepper PJ
    Br J Clin Pharmacol; 1976 Dec; 3(6):1033-9. PubMed ID: 22216526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites.
    Puttonen J; Kantele S; Kivikko M; Häkkinen S; Harjola VP; Koskinen P; Pentikäinen PJ
    Clin Pharmacokinet; 2007; 46(3):235-46. PubMed ID: 17328582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-dose kinetics and dosage of mecillinam in renal failure and haemodialysis.
    Schapira A
    Clin Pharmacokinet; 1984; 9(4):364-70. PubMed ID: 6088153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis.
    Fillastre JP; Taburet AM; Fialaire A; Etienne I; Bidault R; Singlas E
    Drugs Exp Clin Res; 1993; 19(1):25-32. PubMed ID: 8223137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of cefotetan in patients with end-stage renal failure on maintenance dialysis.
    Browning MJ; Holt HA; White LO; Chapman ST; Banks RA; Reeves DS; Yates RA
    J Antimicrob Chemother; 1986 Jul; 18(1):103-6. PubMed ID: 3463556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
    Parasrampuria DA; Marbury T; Matsushima N; Chen S; Wickremasingha PK; He L; Dishy V; Brown KS
    Thromb Haemost; 2015 Apr; 113(4):719-27. PubMed ID: 25566930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of tinidazole in chronic renal failure and in patients on haemodialysis.
    Flouvat BL; Imbert C; Dubois DM; Temperville BP; Roux AF; Chevalier GC; Humbert G
    Br J Clin Pharmacol; 1983 Jun; 15(6):735-41. PubMed ID: 6871072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of sotalol after chronic administration to patients with renal insufficiency.
    Berglund G; Descamps R; Thomis JA
    Eur J Clin Pharmacol; 1980 Oct; 18(4):321-6. PubMed ID: 7439252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elimination of oral cimetidine in chronic renal failure and during haemodialysis.
    Bjaeldager PA; Jensen JB; Larsen NE; Hvidberg EF
    Br J Clin Pharmacol; 1980 Jun; 9(6):585-92. PubMed ID: 7387814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetics of ciprofloxacin in patients with impaired renal function.
    Boelaert J; Valcke Y; Schurgers M; Daneels R; Rosseneu M; Rosseel MT; Bogaert MG
    J Antimicrob Chemother; 1985 Jul; 16(1):87-93. PubMed ID: 2931415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels and half-life of sotalol in chronic renal failure.
    Sundquist HK; Anttila M; Forsström J; Kasanen A
    Ann Clin Res; 1975 Dec; 7(6):442-6. PubMed ID: 1211858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of oral charcoal and urine pH on sotalol pharmacokinetics.
    Kärkkäinen S; Neuvonen PJ
    Int J Clin Pharmacol Ther Toxicol; 1984 Aug; 22(8):441-6. PubMed ID: 6092287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis.
    Singlas E; Taburet AM; Landru I; Albin H; Ryckelinck JP
    Eur J Clin Pharmacol; 1987; 31(5):589-93. PubMed ID: 3830244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of sotalol during pregnancy.
    O'Hare MF; Leahey W; Murnaghan GA; McDevitt DG
    Eur J Clin Pharmacol; 1983; 24(4):521-4. PubMed ID: 6861867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sotalol and end-stage renal failure.
    Patrick GM; Pollock CA; Ibels LS; Caterson RJ
    Aust N Z J Med; 1994 Jun; 24(3):319-20. PubMed ID: 7980222
    [No Abstract]   [Full Text] [Related]  

  • 18. [Pharmacokinetics of azlocillin in chronic renal failure and hemodialysis patients].
    Fillastre JP; Humbert G; Leroy A; Godin M
    Presse Med; 1984 Mar; 13(13):797-801. PubMed ID: 6231597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic aspects of digoxin in patients with terminal renal failure. II. On hemodialysis.
    van der Vijgh WJ
    Int J Clin Pharmacol Biopharm; 1977 Jun; 15(6):255-9. PubMed ID: 881277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis.
    Flouvat B; Decourt S; Aubert P; Potaux L; Domart M; Goupil A; Baglin A
    Br J Clin Pharmacol; 1980 Apr; 9(4):379-85. PubMed ID: 7378254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.